Human GLP-1-analogues that have come to market include liraglutide, dulaglutide, semaglutide, and albiglutide (the last has been withdrawn)
Initial clinical findings suggest that GLP-1 receptor agonists could provide an effective therapeutic strategy in patients with AD and those at risk, however, there remains a lack of sufficient evidence in large clinical samples to draw any firm conclusions
Important compounded-medication context: Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products
After all, Colorado has the lowest rate of obesity in the US outside of DC
People with more weight to lose tend to see faster initial results because their higher metabolic rate creates a larger caloric deficit when appetite decreases
Potential Risks and Side Effects While TRT offers many benefits, its important to understand potential risks (which vary depending on individual health factors)